MX2022007441A - Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. - Google Patents
Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.Info
- Publication number
- MX2022007441A MX2022007441A MX2022007441A MX2022007441A MX2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A
- Authority
- MX
- Mexico
- Prior art keywords
- protein tyrosine
- tyrosine phosphatase
- methods
- phosphatase inhibitors
- ptpn1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/65392—Five-membered rings containing two nitrogen atoms
- C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949613P | 2019-12-18 | 2019-12-18 | |
| PCT/US2020/066104 WO2021127499A1 (en) | 2019-12-18 | 2020-12-18 | Protein tyrosine phosphatase inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007441A true MX2022007441A (es) | 2022-09-02 |
Family
ID=74195125
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007441A MX2022007441A (es) | 2019-12-18 | 2020-12-18 | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. |
| MX2026004270A MX2026004270A (es) | 2019-12-18 | 2022-06-16 | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2026004270A MX2026004270A (es) | 2019-12-18 | 2022-06-16 | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230019236A1 (enExample) |
| EP (1) | EP4077291A1 (enExample) |
| JP (2) | JP7751582B2 (enExample) |
| CN (1) | CN116348455A (enExample) |
| AU (1) | AU2020407648A1 (enExample) |
| CA (1) | CA3162069A1 (enExample) |
| MX (2) | MX2022007441A (enExample) |
| WO (1) | WO2021127499A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3908272B1 (en) | 2019-01-09 | 2023-03-22 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | L-triiodothyronine (t3) for use in limiting microvascular obstruction |
| AU2020401376A1 (en) | 2019-12-12 | 2022-06-30 | Kumquat Biosciences Inc. | Compositions and methods for potentiating immune activity |
| CN118556055A (zh) * | 2021-11-11 | 2024-08-27 | 卡里科生命科学有限责任公司 | 蛋白酪氨酸磷酸酶抑制剂及其使用方法 |
| MX2024005658A (es) * | 2021-11-11 | 2024-08-06 | Calico Life Sciences Llc | Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos. |
| JP2025530135A (ja) * | 2022-09-13 | 2025-09-11 | カムクワット バイオサイエンシーズ インコーポレイテッド | ベンゾ縮合ｎ－複素環及びその使用 |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| TW202519514A (zh) | 2023-07-14 | 2025-05-16 | 天主教魯汶大學 | 新穎化合物(一) |
| CN119818693A (zh) * | 2023-10-13 | 2025-04-15 | 华东师范大学 | 一种用于前药给药系统的可裂解支链连接体化合物及其制备和应用 |
| CN121627562A (zh) * | 2024-09-04 | 2026-03-10 | 南京圣和药业股份有限公司 | 作为wrn抑制剂的化合物及其应用 |
| WO2026112350A1 (en) * | 2024-11-22 | 2026-05-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2026132150A1 (en) | 2024-12-19 | 2026-06-25 | Katholieke Universiteit Leuven | Inhibitors of ptpn 2/ ptpn1 tyrosine phosphatase |
| WO2026132146A1 (en) | 2024-12-19 | 2026-06-25 | Katholieke Universiteit Leuven | Inhibitors of ptpn 2/ ptpn1 tyrosine phosphatase |
| WO2026132149A1 (en) | 2024-12-19 | 2026-06-25 | Katholieke Universiteit Leuven | Inhibitors of ptpn2 and/or ptpn1 |
| WO2026132148A1 (en) | 2024-12-19 | 2026-06-25 | Katholieke Universiteit Leuven | Inhibitors of ptpn2/ptpn1 tyrosine phosphatase |
| WO2026130528A1 (zh) * | 2024-12-20 | 2026-06-25 | 杭州百新生物医药科技有限公司 | Ptpn2/ptpn1抑制剂及其制备方法和医药用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212A (en) | 1847-07-31 | Richard m | ||
| US162A (en) | 1837-04-17 | Island | ||
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| TWI888352B (zh) * | 2018-06-21 | 2025-07-01 | 美商嘉來克生命科學有限責任公司 | 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法 |
| KR102983496B1 (ko) * | 2019-03-14 | 2026-06-29 | 칼리코 라이프 사이언시스 엘엘씨 | 단백질 티로신 포스파타제 억제제 및 이의 사용 방법 |
-
2020
- 2020-12-18 MX MX2022007441A patent/MX2022007441A/es unknown
- 2020-12-18 CA CA3162069A patent/CA3162069A1/en active Pending
- 2020-12-18 EP EP20845275.5A patent/EP4077291A1/en active Pending
- 2020-12-18 WO PCT/US2020/066104 patent/WO2021127499A1/en not_active Ceased
- 2020-12-18 AU AU2020407648A patent/AU2020407648A1/en active Pending
- 2020-12-18 CN CN202080097033.6A patent/CN116348455A/zh active Pending
- 2020-12-18 JP JP2022538083A patent/JP7751582B2/ja active Active
-
2022
- 2022-06-16 MX MX2026004270A patent/MX2026004270A/es unknown
- 2022-06-16 US US17/807,292 patent/US20230019236A1/en active Pending
-
2025
- 2025-09-26 JP JP2025159693A patent/JP2026004380A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230019236A1 (en) | 2023-01-19 |
| JP7751582B2 (ja) | 2025-10-08 |
| WO2021127499A1 (en) | 2021-06-24 |
| CA3162069A1 (en) | 2021-06-24 |
| JP2023507774A (ja) | 2023-02-27 |
| JP2026004380A (ja) | 2026-01-14 |
| EP4077291A1 (en) | 2022-10-26 |
| CN116348455A (zh) | 2023-06-27 |
| AU2020407648A1 (en) | 2022-06-30 |
| MX2026004270A (es) | 2026-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001723A1 (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
| CO2021000447A2 (es) | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso | |
| MX2023002953A (es) | Inhibidores de proteína tirosina fosfatasa y métodos para su uso. | |
| UY38999A (es) | Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| CO2026004964A2 (es) | Moduladores de kras | |
| CR20240360A (es) | Inhibidores de proteína tirosina fosfatasa y usos de estos | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| CO2021001472A2 (es) | Inhibidores de transglutaminasa 2 (tg2) | |
| CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| CL2021001488A1 (es) | Transposasa de piggybac mutada | |
| MX2020014303A (es) | Inhibición de la proteína de union a creb (cbp). | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| CL2020001089A1 (es) | Compuestos inhibidores de tirosina cinasa de bruton (btk). | |
| CL2023002120A1 (es) | Terapia combinada de un inhibidor de alk2 y un inhibidor de jak2 | |
| ECSP21042779A (es) | Moduladores de la expresión de irf5 | |
| MX2023012782A (es) | Composiciones de factor de crecimiento para el tratamiento de enfermedades oculares. |